Biology subjects

Cosson, C.

Publications and source records attributed to Cosson, C..

3 recordsLinked to original sources

bioRxiv2026

CRY-NLRP3 complexes define a circadian checkpoint controlling inflammasome activation

Innate immune sensors such as the NLRP3 inflammasome can trigger inflammatory responses within minutes, raising the question of how circadian clocks influence such rapid decisions. Here, we identify a protein-level circadian checkpoint that links core clock components to NLRP3 inflammasome activation. We show that NLRP3 associates with the circadian repressors CRY1 and CRY2, forming oscillatory complexes that restrain inflammasome activation and rapidly dissociate upon stimulation. Pharmacological stabilization of CRY proteins preserves CRY-NLRP3 association and attenuates inflammasome assembly, IL-1{beta} secretion and pyroptotic cell death in primary human macrophages. In synchronized macrophages, both NLRP3 inflammasome activation and its inhibition by the NLRP3 inhibitor MCC950 vary with circadian time. Finally, a subset of NLRP3 variants reported in cohorts of patients with Cryopyrin-Associated Periodic Syndromes (CAPS), a group of hereditary fever syndromes caused by mutations in NLRP3, weaken CRY binding and are associated with altered time-of-day patterns of inflammasome activation and MCC950 responsiveness. Together, these findings define CRY-NLRP3 complexes as a circadian checkpoint that modulates inflammasome activity and drug response, revealing time of day as a critical dimension of NLRP3-driven inflammation.

immunology↗

bioRxiv2023

Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.

NLRP3-associated autoinflammatory disease (NLRP3-AID or CAPS) is an heterogenous group of monogenic autoinflammations associated with NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants is a barrier to diagnosis although patients can be efficiently treated with anti-IL-1 approaches. In addition, while NLRP3 inflammasome is controlled by coordinated priming and activation signals, gain-of-functions of NLRP3 variants have been only investigated in response to priming. Here, we functionally characterize 34 NLRP3 variants in vitro by determining their activity in response to induction, priming and/or activation signals, and their sensitivity to inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on their profile of signals required for their activation, that correlate partly with the symptoms severities. We identify a new group of NLRP3 mutants responding to the activation signal without priming, with patients often misdiagnosed. Our results identify key NLRP3 residues controlling the inflammasome activity and sensitivity to inhibitors. The comparison of four inhibitors on the 34 variants identifies inhibitory mechanisms with broader efficiency for future drug design. Altogether, our results provide new insights on NLRP3 activation and an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and anti-inflammatory disease drug development. eTOC SummaryFunctional characterization of 34 CAPS-associated NLRP3 variants identifies polymorphisms versus gain-of-function pathogenic mutants, and highlights diversities in the signals controlling their activation and in their sensitivity to inhibitors. This study provides tools for CAPS diagnosis and anti-inflammation drug development and insights on NLRP3 control mechanisms.

immunology↗

bioRxiv2019

Centrosome amplification favours survival and impairs ovarian cancer progression

Centrosome amplification, the presence of more than two centrosomes in a cell is a common feature of most human cancer cell lines. However, little is known about centrosome numbers of human cancers and whether amplification or other numerical aberrations are frequently present. To address this question, we have analyzed a large cohort of human epithelial ovarian cancers (EOCs) from 100 patients. Using state-of-the-art microscopy, we have determined the Centrosome-Nucleus Index (CNI) of each tumor. We found that EOCs show infrequent centrosome amplifications. Strikingly, the large majority of these tumors presented low CNIs. We show that low CNI tumors are enriched in the mesenchymal subgroup and correlate with poor patient survival. Our findings highlight a novel paradigm linking low centrosome number with highly aggressive behavior in ovarian cancers and show that the CNI signature may be used to stratify ovarian cancers.

cancer biology↗